Biosimilars in Oncology
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare. Biologic drugs are some of the most expensive medicines to develop, as they are large complex molecules. Biosimilars are highly similar to approved biologic drugs, with no clinically relevant differences, and aim to achieve the same clinical results at a lower price than their originator molecules. This is a key way in which the cost-savings required to promote sustainability can be achieved.
In oncology, biosimilar versions of six biologic drugs are now available. The EMA has pioneered regulatory acceptance of biosimilars, and has approved many more biosimilars than the FDA. Beyond the major markets of the US and 5EU (France, Germany, Italy, Spain and UK), two emerging markets are important in the oncology biosimilars landscape: India, with the most approved biosimilars globally, and South Korea, home to major biosimilar developer Celltrion.
This report provides an assessment of the current oncology biosimilars landscape in the 9MM (US, 5EU, Japan, India and South Korea), including market potential, current and expected use of biosimilars, clinical and commercial concepts, regulatory pathways, important indications, and an overview of leading and emerging developers.
Scope
GlobalData’s Biosimilars in Oncology report combines primary research from oncology experts and a high prescribing physicians’ survey with in-house analyst expertise to provide an assessment of the marketplace.
Components of the slide deck include primary and secondary research:
• Quotes from 11 US-, 5EU-, Japan-, and India-based experts, including Key Opinion Leaders (KOLs) and payers
• Quantitative survey information from 107 US-, 5EU-, India-, South Korea-based high-prescribing physicians
• Summary of key clinical and commercial concepts for biosimilars
• Overview of biosimilar regulatory pathways across key markets
• Analysis of potential of each key biosimilars market
• Outline of important indications for oncology biosimilars
• Review of key biosimilar developers and their portfolios
• Insight from GlobalData’s specialist oncology analysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of the oncology biosimilar landscape and its key players.
Organize your efforts by understanding the market potential and current regulatory outlook shaping the oncology biosimilars landscape in key markets.
Develop strategies by understanding expert and high prescriber perceptions of biosimilars, and drivers for current use patterns and expected changes in use.
Alkem Laboratories
Amgen
Apobiologix
Apotex
Archigen Biotech
Biocon
Bio-Thera
Boehringer Ingelheim
Cadila Healthcare
Celltrion
Centus Biotherapeutics
Cinfa Biotech
Cipla
Claris Lifesciences
Coherus BioSciences
CT Arzneimittel
Daewoong Pharmaceutical
Daiichi Sankyo
Dr. Reddy’s Laboratories
EirGenix
Emcure Pharmaceuticals
Fuji Pharma
Gedeon Richter
Glenmark Pharmaceuticals
Hetero Drugs
Hexal
Hospira
InnoVent
Intas Pharmaceuticals
Kissei Pharmaceutical
Kyowa Hakko Kirin
Lupin
Mabion
mAbxience
Medice Arzneimittel Putter
Meiji Seika Pharma
Merck & Co
Mochida Pharmaceutical
Mylan
Nippon Kayaku
Pfizer
Panacea Biotec
Prestige BioPharma
Prolong Pharmaceuticals
Ratiopharm
Reliance Life Sciences
Samsung Bioepis
Sandoz
Synthon Holdings
Tanvex BioPharma
Teva
Torrent Pharmaceuticals
USV
Wockhardt
Zenotech Laboratories
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports

